First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer - Trial NCT06398743
Access comprehensive clinical trial information for NCT06398743 through Pure Global AI's free database. This phase not specified trial is sponsored by Exact Sciences Corporation and is currently Recruiting. The study focuses on Colorectal Cancer. Target enrollment is 400 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Exact Sciences Corporation
Timeline & Enrollment
N/A
Jun 20, 2023
Jun 15, 2029
Primary Outcome
To validate the association of post-definitive therapy and pre-recurrence follow-up ctDNA positivity with Recurrence Free Interval, defined as elapsed time from surgical resection to the first clinical recurrence or CRC-related death.
Summary
The CORRECT - MRD I study will prospectively enroll patients who have undergone complete
 surgical resection for stage II or III colorectal cancer. Patients will be followed for up to
 5 years for recurrence.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06398743
Device Trial